Related Experiment Videos
[Dendritic cell therapy]
1Department of Transfusion Medicine, University of Tokyo Hospital.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|January 5, 2002
Summary
Dendritic cell (DC) therapy showed promise against chronic myelogenous leukemia (CML) in a small trial. While safe and inducing immune responses, further studies are needed to confirm clinical effectiveness in CML patients.
Area of Science:
- Immunology
- Oncology
- Cell Therapy
Context:
- Dendritic cells (DCs) are potent antigen-presenting cells crucial for initiating T cell responses.
- DCs have shown success in clinical studies for inducing tumor-specific immunity.
- Chronic myelogenous leukemia (CML) remains a significant hematologic malignancy requiring novel therapeutic strategies.
Purpose:
- To evaluate the safety and immunogenicity of dendritic cell (DC) therapy targeting chronic myelogenous leukemia (CML).
- To assess the clinical response in CML patients receiving CML-specific peptide-pulsed autologous DCs.
Summary:
- Three CML patients received four infusions of autologous DCs pulsed with bcr/abl peptides.
- The DC vaccination was well-tolerated, with no observed autoimmunity.
- Immune responses, including delayed-type hypersensitivity (DTH), were detected in patients, with one showing a positive DTH reaction to the peptide-pulsed DCs.
- No clinical responses were observed in the treated patients.
Impact:
- DC therapy is a potentially safe approach for CML treatment.
- The study highlights the need for further investigation to establish the clinical efficacy and survival impact of DC-based immunotherapy in CML.
- This research contributes to the understanding of cellular immunotherapy in hematologic malignancies.